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Background: We sought to build prognostic nomograms and 
identify novel prognostic factors in small-cell lung cancer 
(SCLC) incorporating both clinical data and peripheral blood 
markers.
Methods: We analyzed 938 patients with SCLC (555 extensive stage 
SCLC [ES-SCLC] and 383 limited stage SCLC [LS-SCLC]) diag-
nosed between 1997 and 2012 from a single institution. We investi-
gated the prognostic value of pretreatment neutrophil to lymphocyte 
ratio, platelet to lymphocyte ratio, red cell distribution width, hemo-
globin, and other clinicopathological factors. Cox proportional haz-
ards models determined the effects of multiple factors on overall 
survival (OS). Two nomograms were developed to predict median 
survival and 6- and 12-month OS for ES-SCLC, and 1- and 2-year 
OS for LS-SCLC.
Results: In ES-SCLC, the multivariate Cox model identified neutro-
phil to lymphocyte ratio and red cell distribution width as significant 
prognostic factors for OS independent of age, Eastern Cooperative 
Oncology Group performance score, chest radiation, chemotherapy, 
liver metastases, and numbers of metastatic sites. In LS-SCLC, sig-
nificant prognostic variables included platelet to lymphocyte ratio, 
age, smoking cessation, chest radiation, chemotherapy, surgery, and 
prophylactic cranial irradiation. The two nomograms show good 
accuracy in predicting OS, with a concordance index of 0.73 in both 
ES- and LS-SCLC.
Conclusion: The two nomograms incorporating hematological 
markers could more accurately predict individualized survival prob-
ability of SCLC than the existing models.
Key Words: Small-cell lung cancer, Survival, Prediction model, 
Nomogram, Neutrophil to lymphocyte ratio, Hematological markers.
(J Thorac Oncol. 2015;10: 1213–1220)
Approximately 14% of all lung cancer cases (more than 30,000 patients) in the US have small-cell lung can-
cer (SCLC).1,2 SCLC treatment remains unsatisfying, as 
minimal breakthroughs have occurred in the past decade. 
Despite high initial responses to therapy, most patients 
die from recurrent disease, and the median survival after 
diagnosis is estimated to be 8–20 months. To better predict 
the SCLC patients’ outcomes, various prognostic factors 
and models have been investigated, such as age, gender, 
performance score (PS), serum neuron-specific enolase 
(NSE), serum lactate dehydrogenase, the Spain prognos-
tic index,3 and the Manchester Score.4 The development of 
novel prognostic factors and models will enable a better 
treatment stratification for patients with SCLC.
Statistical prediction models are widely used for 
predicting cancer outcomes. Among those, the nomogram 
is a graphical presentation of the results from a statistical 
model, which utilizes combined prognostic factors in pre-
dicting outcome for a given patient. Individualized esti-
mation of survival among patients with cancer could be 
useful for counseling patients in making treatment deci-
sions and optimizing therapeutic approaches. However, 
to the best of our knowledge, no nomogram has been 
reported for SCLC.
Inflammation is a known critical component of can-
cer progression.5 Neutrophil to lymphocyte ratio (NLR) 
and platelet to lymphocyte ratio (PLR) in peripheral blood 
have been proposed as reliable indicators of the host’s 
inflammatory status; they have been identified as both 
prognostic and predictive biomarkers in many types of 
cancer including non–small-cell lung cancer.6–8 Recently, 
two studies have shown that elevated red cell distribu-
tion width (RDW) level is also a marker of poor prognosis 
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TABLE 1.  Characteristics of All SCLC by Stage
Characteristic
ES-SCLC (n = 555) LS-SCLC (n = 383)
pNo. (%) No. (%)
Age at diagnosis 0.9499
  Mean (SD) 66.7 (10.3) 66.7 (10.0)
Gender 0.0032
  Female 237 (42.7%) 201 (52.5%)
  Male 318 (57.3%) 182 (47.5%)
Smoking status 0.3384
  Never 12 (2.2%) 5 (1.3%)
  Former 200 (36.0%) 151 (39.4%)
  Current 343 (61.8%) 227 (59.3%)
Pack-year 0.0025
  Missing 49 (0.0%) 21 (0.0%)
  0–19 47 (9.3%) 16 (4.4%)
  20–39 132 (26.1%) 74 (20.4%)
  40–59 138 (27.3%) 127 (35.1%)
  >60 189 (37.4%) 145 (40.1%)
Smoking cessation 0.0693
  Quit or never smoker 375 (67.6%) 280 (73.1%)
  Never quit 180 (32.4%) 103 (26.9%)
ECOG performance status <0.0001
  <2 399 (71.9%) 331 (86.4%)
  ≥2 156 (28.1%) 52 (13.6%)
BMI 0.4278
  Missing 14 (0.0%) 7 (0.0%)
  <25 187 (34.6%) 142 (37.8%)
  25–30 230 (42.5%) 144 (38.3%)
  >30 124 (22.9%) 90 (23.9%)
Therapy <0.0001
  No treatment 114 (20.5%) 19 (5.0%)
  Surgery with adjuvant therapy 6 (1.1%) 52 (13.6%)
  Chemotherapy or chest radiation only 292 (52.6%) 75 (19.6%)
  Chemotherapy plus chest radiation 143 (25.8%) 237 (61.9%)
Chemotherapy <0.0001
  No 125 (22.5%) 36 (9.4%)
  Yes 430 (77.5%) 347 (90.6%)
Chest radiation <0.0001
  No 399 (71.9%) 126 (32.9%)
  Yes 156 (28.1%) 257 (67.1%)
PCI <0.0001
  No 536 (96.6%) 293 (76.5%)
  Yes 19 (3.4%) 90 (23.5%)
Platinum agent 0.0042
  No chemotherapy 125 (0.0%) 36 (0.0%)
  No 41 (9.5%) 13 (3.7%)
  Yes 376 (87.4%) 318 (91.6%)
  Unknown 13 (3.0%) 16 (4.6%)
Chemotherapy-agent combination 0.0022
  No chemotherapy 125 (0.0%) 36 (0.0%)
  VP16 + CDDP/CBP 351 (81.6%) 305 (87.9%)
  Other combination 66 (15.3%) 26 (7.5%)
  Unknown 13 (3.0%) 16 (4.6%)
(Continued)
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in non–small-cell lung cancer.9,10 However, there is little 
information on prognostic relevance of the pretreatment 
NLR, PLR, and RDW in SCLC.
Therefore, we conducted this study to investigate the 
prognostic relevance of NLR, PLR, and RDW with regard to 
the overall survival (OS), stratified for patients with extensive 
stage SCLC (ES-SCLC) and limited stage SCLC (LS-SCLC). 
We also sought to develop two prognostic nomograms that 
incorporate NLR, PLR, RDW, and other important clinico-
pathological variables.
MATERIALS AND METHODS
Study Cohort and Data Collection
Since 1997, all patients with a pathologic diagno-
sis of primary lung cancer evaluated and treated at Mayo 
Clinic, Rochester, MN, have been prospectively enrolled 
and followed for outcome research, using protocols 
approved by the Mayo Clinic Institutional Review Board 
(IRB Number: 225–99), and all participants have provided 
written informed consent. Detailed procedures of patient 
enrollment, diagnosis, data collection, and follow-up have 
been described in previous publications.11 Between January 
1, 1997 and December 31, 2012, a total of 1558 patients 
with a pathologically confirmed diagnosis of SCLC have 
been enrolled. Of these, 938 SCLC cases met our study 
inclusion criteria as they had a complete blood count with 
leukocyte differential performed before any treatment. 
Excluded from consideration were patients with leukemia or 
lymphoma. We excluded all atypical NETs and mixed types 
of SCLC. A full medical record abstraction was carried out 
to obtain demographics, history of tobacco exposure, lung 
cancer pathologic type, clinical staging, and treatment. 
All patients were actively followed up. Annual verification 
Liver metastases at baseline
  No 328 (59.1%)
  Yes 227 (40.9%)
Numbers of metastatic sites at baseline
  <2 369 (66.5%)
  ≥2 186 (33.5%)
NLR <0.0001
  Median (range) 4.4 (0.2–60.3) 3.1 (0.2–56.7)
PLR 0.0001
  Median (range) 190.0 (2.3–3944.4) 160.1 (23.4–1034.8)
RDW 0.0189
  Median (range) 13.5 (10.1–24.5) 13.3 (11.3–23.3)
Hemoglobin (g/dl) 0.8319
  Median (range) 13.4 (4.3–20.4) 13.3 (8.0–18.1)
Any other cancer 0.4722
  No 458 (82.5%) 309 (80.7%)
  Yes 97 (17.5%) 74 (19.3%)
COPD 0.0104
  No 415 (74.8%) 257 (67.1%)
  Yes 140 (25.2%) 126 (32.9%)
Diabetes 0.8326
  No 488 (87.9%) 335 (87.5%)
  Yes 67 (12.1%) 48 (12.5%)
Cardiovascular disease 0.1060
  No 408 (73.5%) 263 (68.7%)
  Yes 147 (26.5%) 120 (31.3%)
SCS 0.0415
  <9 473 (85.2%) 307 (80.2%)
  ≥9 82 (14.8%) 76 (19.8%)
ES-SCLC, extensive stage small-cell lung cancer; LS-SCLC, limited stage small-cell lung cancer; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, 
red cell distribution width; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; PCI, prophylactic cranial irradiation; CDDP, cisplatinum; CBP, carboplatinum; 
COPD, chronic obstructive pulmonary disease; SCS, simplified comorbidity score.
TABLE 1. (Continued)
Characteristic
ES-SCLC (n = 555) LS-SCLC (n = 383)
pNo. (%) No. (%)
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of patients’ vital status was accomplished through Mayo 
Clinic’s electronic medical records and registration data-
base, next-of-kin reports, death certificates, and obituary 
documents filed in the patients’ medical records, as well 
as through the Mayo Clinic Tumor Registry and Social 
Security Death Index website.
Analyses were applied separately in ES- and 
LS-SCLC. The NLR was categorized into two groups 
based on a cut-off value of 56,12. Optimal cut-off points for 
the PLR was selected using log-rank statistics,13 with the 
optimal dichotomizing cut point for the PLR, hemoglobin, 
and RDW at 210, 12, and 15, respectively.14 When neces-
sary, natural log transformations of continuous variables 
were calculated for several laboratory values including 
NLR, PLR, and RDW to reduce the distribution skewness. 
A simplified comorbidity score was calculated to evaluate 
comorbidity conditions.15
Statistical Analysis
Clinical data are reported as mean ± standard devia-
tion or median (full range). Cumulative survival is estimated 
with a Kaplan–Meier model using the time of diagnosis as 
the starting point. Univariate and multivariate Cox propor-
tional hazards models are used to assess prognostic factors 
including clinicopathological variables and pretreatment 
hematologic markers (i.e., continuous or dichotomized lev-
els when appropriate).
Cox Proportional Hazards models determined the 
effects of multiple factors on a nomogram, and only the fac-
tors with a p value less than 0.05 were incorporated into the 
nomogram. Two separate nomograms were developed, one 
for ES-SCLC and another for LS-SCLC, to predict median 
survival and 6- and 12-month OS, or 1- and 2-year OS, 
respectively.
The performance of the nomogram is assessed using 
the concordance index (C-index) and calibration curve. The 
predictive accuracy of OS is estimated using the C-index. 
A larger C-index is associated with a more accurate prog-
nostic prediction. Two hundred bootstrap resamples were 
used for internal validation of the accuracy of predictions 
and to avoid overfitting the model. Calibration refers to 
whether the predicted probabilities agree with observed 
probabilities, which is generated by plotting the predicted 
survival probabilities against the actuarial outcome. In 
a well-calibrated model, the calibration curve should be 
close to 45°.
All statistical analyses were carried out using SAS 9.3 
(SAS Institute Inc., Cary, NC) and R version 3.0.2 (The R 
Foundation for Statistical Computing, Vanderbilt University, 
Nashville, TN) with the rms and survival libraries. All p values 
were two-tailed.
RESULTS
Characteristics of All Patients
With a median follow-up time of 10.8 months, 856 deaths 
(91.3% of the 938 total) have been observed. The median age 
at the time of diagnosis was 68 years (range 27–91 years). 
The median follow-up time for the surviving patients was 7.8 
years. Nine hundred twenty-one (921) patients (98.8%) were 
former or current smokers.
TABLE 2.  Multicovariate Cox Regression Model for Overall 
Survival in Extensive Stage SCLC
Variable HR (95% CI) p
Log
e
 (RDW) 2.81 (1.32–6.01) 0.0093
Log
e
 (NLR) 1.41 (1.24–1.59) <0.0001
PLR (vs. <210)
  ≥210 0.827 (0.672–1.017) 0.0718
Age at diagnosis 1.01 (1.001–1.02) 0.0304
Gender (vs. female)
  Male 1.15 (0.97–1.37) 0.1128
ECOG performance status (vs. <2)
  ≥2 1.68 (1.25–2.24) 0.0008
Chest radiation (vs. no)
  Yes 0.809 (0.66–0.99) 0.0376
Chemotherapy (vs. no)
  Yes 0.24 (0.18–0.34) <0.0001
Liver metastases (vs. no)
  Yes 1.23 (1.03–1.48) 0.0263
Numbers of metastatic sites (vs. <2)
  ≥2 1.39 (1.15–1.67) 0.0007
NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, red 
cell distribution width; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; 
SCLC, small-cell lung cancer; CI, confidence interval.
TABLE 3.   Multicovariate Cox Regression Model for Overall 
Survival in Limited Stage SCLC
Variable HR (95% CI) p
PLR (vs. <210)
  ≥210 1.60 (1.18–2.18) 0.0028
Log
e
 (NLR) 1.16 (0.96–1.42) 0.1299
Log
e
 (RDW) 0.84 (0.24–2.94) 0.7850
Hemoglobin (g/dl; vs. ≥12)
  <12 1.19 (0.88–1.61) 0.2571
Age at diagnosis 1.03 (1.02–1.05) <0.0001
ECOG performance status (vs. <2)
  ≥2 0.94 (0.66–1.34) 0.7184
Smoking cessation (vs. quit)
  Never quit 1.47 (1.14–1.90) 0.0041
Chest radiation (vs. no)
  Yes 0.39 (0.29–0.52) <0.0001
Chemotherapy (vs. no)
  Yes 0.19 (0.13–0.30) <0.0001
Surgery (vs. no)
  Yes 0.35 (0.23–0.52) <0.0001
PCI (vs. no)
  Yes 0.65 (0.49–0.88) 0.0035
NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, red 
cell distribution width; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; 
PCI, prophylactic cranial irradiation; CI, confidence interval.
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Prognostic Effect of Blood Markers
The demographics and clinical information of 555 
ES-SCLC and 383 LS-SCLC patients are summarized in 
Table 1. Elevated PLR, NLR, and RDW were associated with 
extensive stage disease. Supplementary Table 1 (SDC 1, http://
links.lww.com/JTO/A846) shows the 6 month, 1-, 2-, and 
3-year survival by hematological markers. Low hemoglobin 
(p = 0.008) and elevated PLR (p < 0.0001), NLR (p < 0.0001) 
and RDW (p < 0.0001) were significantly associated with a 
worse prognosis (Supplementary Table 1, SDC 1, http://links.
lww.com/JTO/A846).
Kaplan–Meier survival estimates for NLR, PLR, 
RDW, and hemoglobin are shown in Supplementary Figures 
1–4 (SDC 2, http://links.lww.com/JTO/A847). In ES-SCLC, 
elevated NLR (p < 0.001) and RDW (p < 0.001) were asso-
ciated with poor prognosis. In LS-SCLC, low hemoglobin 
(p = 0.048), elevated PLR (p = 0.001), and NLR (p = 0.044) 
were associated with poor prognosis.
Nomograms Development
In univariate analysis, NLR, RDW, PLR, age, gender, 
Eastern Cooperative Oncology Group (ECOG) PS, chest 
radiation, chemotherapy, liver metastases, and numbers of 
metastatic sites at diagnosis were significantly associated 
with OS in ES-SCLC (Supplementary Table 2, SDC 1, http://
links.lww.com/JTO/A846). For patients with LS-SCLC, 
possible predictors for OS included PLR, age, smoking ces-
sation, chest radiation, chemotherapy, ECOG PS, surgery 
and prophylactic cranial irradiation (PCI) (Supplementary 
Table 3, SDC 1, http://links.lww.com/JTO/A846).
Tables 2 and 3, respectively, summarize the findings of 
the multivariate Cox proportional hazards analyses in ES- and 
FIGURE 1.  Nomogram for 6- and 12-month survival and median survival for extensive stage SCLC patients, including data 
derived from 555 patients and 547 mortality events. The nomogram is used by adding up the points identified on the points 
scale for each variable. The total projected on the bottom scale indicates the probability of 6- and 12-month survival and 
median survival. SCLC, small-cell lung cancer; NLR, neutrophil to lymphocyte ratio; RDW, red cell distribution width; PS, Eastern 
Cooperative Oncology Group performance status; Liver metastases, liver metastases at baseline; Metastatic sites, numbers of 
metastatic sites at baseline.
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LS-SCLC. All significant prognostic variables were used to 
build the nomograms.
The nomogram of ES-SCLC included the following 
variables: NLR, RDW, age at diagnosis, ECOG PS, che-
motherapy, chest radiation, liver metastases, and numbers 
of metastatic sites (Fig. 1). The nomogram assigned points 
based on NLR and RDW in a continuous but nonlinear fash-
ion. Outcomes were reported as 6 and 12 months OS and 
median survival. The nomogram of LS-SCLC included the 
following variables: PLR, age at diagnosis, smoking ces-
sation, chemotherapy, chest radiation, surgery, and PCI 
(Fig. 2). Outcomes were reported as 1- and 2-year OS and 
median survival.
Nomograms Validation
The nomograms that predicted OS were well calibrated 
with the Kaplan–Meier observed OS at 6 and 12 months in 
ES-SCLC (Supplementary Figure 5, SDC 2, http://links.
lww.com/JTO/A847) and at 1 and 2 years in LS-SCLC 
(Supplementary Figure 6, SDC 2, http://links.lww.com/JTO/
A847). The bootstrap C-index of the nomogram were both 
0.73. A histogram of nomogram-predicted probabilities 
is shown in Figure 3 and illustrates the heterogeneity in 
predicted outcome within two stages.
DISCUSSION
We have developed and internally validated two nomo-
grams that assign predictions for OS based on NLR, PLR, 
RDW, and other clinicopathological variables in a series of 
938 patients from a single institution. We propose that the two 
nomograms provide more individualized OS predictions and 
could help patients and clinicians in the treatment decision-
making process.16
Cancer-associated inflammation is a key determinant 
of tumor progression and survival. Elevated NLR,6–8,17,18 
PLR, and RDW10 in the peripheral blood of cancer patients 
may reflect the extent of systemic inflammation elicited by 
cancer cells, which have been identified as poor prognostic 
markers in many types of cancer. A definitive explanation 
underlying these findings has not been clearly elucidated 
yet. The systemic inflammatory reaction results in neu-
trophilia, thrombocytosis, and relative lymphocytopenia. 
Elevated NLR and PLR may reflect relatively depleted lym-
phocyte populations, possibly impairing the host immune 
FIGURE 2.  Nomogram for 1- or 2-year survival and median survival for limited stage SCLC patients, including data derived from 
383 patients and 314 mortality events. The nomogram is used by adding up the points identified on the points scale for each vari-
able. The total projected on the bottom scale indicates the probability of 1- or 2-year survival and median survival. SCLC, small-cell 
lung cancer; PLR, platelet to lymphocyte ratio; PCI, prophylactic cranial irradiation; surgery, surgery with adjuvant therapy.
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response to malignancy. In SCLC, thrombocytosis was also 
found to indicate a poor prognosis.19 RDW was thought to 
be associated with the increased systemic inflammation or 
malnutrition induced by cancer progression.10
In our study, elevated NLR and RDW represent signif-
icant independent prognostic indicators in ES-SCLC (log
e
 
NLR, hazard ratio [HR] = 1.41, 95% confidence interval 
[CI]: 1.24–1.59, p < 0.0001; log
e
 RDW, HR = 2.81, 95% 
CI: 1.32–6.01, p = 0.0093). Elevated PLR was associated 
with significantly worse outcomes (HR = 1.60; 95% CI: 
1.18–2.18; p = 0.0028) in LS-SCLC. Most of the former 
studies use categorical variables of NLR or RDW to assess 
the prognosis. We found that both continuous and categori-
cal variables of NLR and RDW are significant independent 
prognostic indicators (results not shown). When building 
a nomogram in ES-SCLC, we modeled NLR and RDW as 
continuous variables because continuous variables could 
preserve more information than categorical variables.
In addition to NLR, PLR, and RDW, we identified that 
age, chemotherapy, and chest radiation were independent 
prognostic factors in both ES- and LS-SCLC. Other inde-
pendent prognostic factors included smoking cessation, 
PCI, and surgery in LS-SCLC, and PS, liver metastases and 
number of metastatic sites in ES-SCLC. These are consistent 
with previous reports.20,21
SCLC is relatively homogeneous as most patients are 
treated with chemotherapy and/or radiation, yet survival out-
comes vary from one individual to another. Patient progno-
sis is currently estimated on the basis of the old Veterans’ 
Administration and AJCC TNM staging classification,22 not 
on other factors like age, gender, smoking, or PS. By inte-
grating additional significant prognostic factors, a nomogram 
could be applied to more accurately estimate an individual 
patient’s survival. Based on statistical models, our nomo-
grams allow for individualized survival probability estima-
tion for ES- and LS-SCLC, which discriminate better than 
the older Veterans’ Administration staging system (Fig. 3). 
Several scoring systems have been established for the prog-
nosis of SCLC, such as the Spain prognostic index3 and the 
Manchester Score.4 Moreover, our nomograms are better 
FIGURE 3.  Histogram of nomogram-predicted overall survival. Note: the heterogeneity of predicted probabilities of time to 
recurrence within each stage.
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able to predict OS for individual patients than the scoring 
systems that stratify patients into a few risk groups. In addi-
tion, the nomograms have great potential of estimating risk 
in clinical trial design, which could be used for stratification 
in randomized studies based on their survival probability.
The performance of a nomogram needs to be assessed 
by calibration and discrimination. The C-index reflects the 
predictive accuracy of a nomogram. In this study, internal 
validation demonstrated good discrimination power (C-index, 
0.73 in both ES- and LS-SCLC). The nomograms were well 
calibrated for predictions of OS (Supplementary Figures 5–6, 
SDC 2, http://links.lww.com/JTO/A847).
Peripheral blood markers would be valuable in SCLC, 
given that most patients with SCLC are not operative candi-
dates and their primary tumors are rarely available for exten-
sive analyses. Assessment of the peripheral blood markers 
may be easier and more cost–effective than conventional 
tumor markers, such as serum NSE and carcinoembryonic 
antigen in clinical practice. We used peripheral blood mark-
ers to build nomograms, which could be readily available for 
validation in any other clinical settings.
There are several limitations to this study. These models 
are based on a specific population treated at a tertiary medical 
center. Our nomograms were built and validated internally, and 
they should be externally validated in a larger number of patients 
at multiple institutions. Finally, we did not include some known 
prognostic factors, such as the level of lactate dehydrogenase, 
albumin, NSE, carcinoembryonic antigen, and other prognos-
tic factors. The addition of these markers in future studies may 
improve the predictive ability of the two nomograms, which is 
also one of the benefits of this type of prognostic model.
CONCLUSION
In summary, we have identified that elevated NLR and 
RDW in ES-SCLC, and elevated PLR in LS-SCLC are poor 
prognostic factors. Our study constitutes the first two nomograms 
to accurately predict individualized survival probability in SCLC. 
These models could assist clinicians and patients in clinical deci-
sion-making and treatment tailoring. These results could be used 
to define proper stratification factors in future clinical trials.
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